{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:45:41Z","timestamp":1790768741273,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11938-017-0133-3","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T06:25:26Z","timestamp":1492583126000},"page":"296-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices"],"prefix":"10.1007","volume":"15","author":[{"given":"Nicole E.","family":"Rich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neehar D.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"issue":"12","key":"133_CR1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular Carcinoma. N Engl J Med. 2011;365(12):1118\u201327.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"133_CR2","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","volume":"17","author":"V Mazzaferro","year":"2011","unstructured":"Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44\u201357.","journal-title":"Liver Transpl"},{"key":"133_CR3","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Heimbach JK, Hirose R, Stock PG, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology. 2015;61(5):1643\u201350. Authors demonstrated a 6\u20139-month delay in receipt of MELD exception points reduces disparity in transplant rates between HCC and non-HCC candidates.","DOI":"10.1002\/hep.27704"},{"issue":"10","key":"133_CR4","first-page":"527","volume":"12","author":"GC Sotiropoulos","year":"2007","unstructured":"Sotiropoulos GC, Molmenti EP, Losch C, et al. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res. 2007;12(10):527\u201334.","journal-title":"Eur J Med Res"},{"issue":"6","key":"133_CR5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.27272","volume":"60","author":"KJ Halazun","year":"2014","unstructured":"Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014;60(6):1957\u201362.","journal-title":"Hepatology"},{"key":"133_CR6","unstructured":"\u2022 Mehta N, Heimbach J, Harnois DM, et al. Short waiting time predicts early recurrence of hepatocellular carcinoma after liver transplantation: a multicenter study supporting the \u201cablate and wait\u201d principle. Paper presented at: The Liver Meeting 2014; Boston, MA. Multi-center study demonstrated liver transplant waiting times less than 6\u00a0months is predictive of post-transplant recurrence of hepatocellular carcinoma."},{"issue":"2","key":"133_CR7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2011.05.020","volume":"56","author":"JH Wang","year":"2012","unstructured":"Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early\/early stage hepatocellular carcinoma. J Hepatol. 2012;56(2):412\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"133_CR8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2010.08.018","volume":"9","author":"HH Hung","year":"2011","unstructured":"Hung HH, Chiou YY, Hsia CY, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9(1):79\u201386.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"133_CR9","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/lt.22129","volume":"16","author":"WE Naugler","year":"2010","unstructured":"Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl. 2010;16(10):1186\u201394.","journal-title":"Liver Transpl"},{"key":"133_CR10","doi-asserted-by":"crossref","unstructured":"\u2022 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention-to-treat outcome of T1 hepatocellular carcinoma with the \u201cwait and not ablate\u201d approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016;22(2):178\u201387. The risk of tumor progression from T1 directly to beyond T2 is low (< 5%) within 6\u00a0months, although the ideal strategy in these patients (immediate ablation vs. watchful waiting) remains unknown.","DOI":"10.1002\/lt.24360"},{"issue":"7","key":"133_CR11","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.26501","volume":"118","author":"H Nathan","year":"2012","unstructured":"Nathan H, Segev DL, Mayo SC, et al. National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer. 2012;118(7):1838\u201344.","journal-title":"Cancer"},{"issue":"2","key":"133_CR12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/TP.0b013e3182a89383","volume":"97","author":"Z Zheng","year":"2014","unstructured":"Zheng Z, Liang W, Milgrom DP, et al. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation. 2014;97(2):227\u201334.","journal-title":"Transplantation"},{"key":"133_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Vitale A, Huo TL, Cucchetti A, et al. Survival benefit of liver transplantation versus resection for hepatocellular carcinoma: impact of MELD score. Ann Surg Oncol. 2015;22(6):1901\u20137. Surgical resection is the cost effective approach to HCC patients with compensated cirrhosis if MELD score is below 10 and there is no evidence of microvascular invasion.","DOI":"10.1245\/s10434-014-4099-2"},{"issue":"2","key":"133_CR14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hep.22648","volume":"49","author":"YK Cho","year":"2009","unstructured":"Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology (Baltimore, Md). 2009;49(2):453\u20139.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"12","key":"133_CR15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/TP.0b013e31816b67e4","volume":"85","author":"SS Zheng","year":"2008","unstructured":"Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726\u201332.","journal-title":"Transplantation"},{"issue":"9","key":"133_CR16","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1111\/j.1600-6143.2010.03222.x","volume":"10","author":"JJ Guiteau","year":"2010","unstructured":"Guiteau JJ, Cotton RT, Washburn WK, et al. An early regional experience with expansion of Milan criteria for liver transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(9):2092\u20138.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"6","key":"133_CR17","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394\u2013403.","journal-title":"Hepatology"},{"issue":"10","key":"133_CR18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/lt.20847","volume":"12","author":"RB Freeman","year":"2006","unstructured":"Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS\/OPTN database. Liver Transpl. 2006;12(10):1504\u201311.","journal-title":"Liver Transpl"},{"key":"133_CR19","doi-asserted-by":"crossref","unstructured":"Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246(3):502\u20139. discussion 509-511","DOI":"10.1097\/SLA.0b013e318148c704"},{"issue":"6","key":"133_CR20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","volume":"65","author":"X Xu","year":"2016","unstructured":"Xu X, Lu D, Ling Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65(6):1035\u201341.","journal-title":"Gut"},{"issue":"2","key":"133_CR21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/ctr.12089","volume":"27","author":"PT Kim","year":"2013","unstructured":"Kim PT, Onaca N, Chinnakotla S, et al. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transpl. 2013;27(2):311\u20138.","journal-title":"Clin Transpl"},{"issue":"6","key":"133_CR22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","volume":"64","author":"G Sapisochin","year":"2016","unstructured":"Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6):2077\u201388.","journal-title":"Hepatology"},{"issue":"6","key":"133_CR23","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","volume":"61","author":"FY Yao","year":"2015","unstructured":"Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968\u201377.","journal-title":"Hepatology"},{"key":"133_CR24","unstructured":"Mehta N, Guy J, Frenette CT, et al. Multicenter Study of Down-staging of hepatocellular carcinoma (HCC) to within Milan criteria before liver transplantation (LT). Paper presented at: The Liver Meeting Boston, MA; 2014"},{"key":"133_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142\u201352. There is variation in post-transplant recurrence rates and post-transplant survival with downstaging, although a priori inclusion criteria, mandatory waiting time prior to transplantation, and a standardized downstaging protocol are the approaches that likely yield the best outcomes.","DOI":"10.1002\/lt.24169"},{"issue":"4","key":"133_CR26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1600-6143.2007.02138.x","volume":"8","author":"ML Volk","year":"2008","unstructured":"Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8(4):839\u201346.","journal-title":"Am J Transplant"},{"issue":"1","key":"133_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35\u201343.","journal-title":"Lancet Oncol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-017-0133-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-017-0133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-017-0133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T07:27:47Z","timestamp":1569050867000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-017-0133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s11938-017-0133-3","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}